COST-EFFECTIVENESS OF CLADRIBINE COMPARED TO NATALIZUMAB, OCRELIZUMAB AND ALEMTUZUMAB FOR THE TREATMENT OF PATIENTS WITH HIGHLY ACTIVE RELAPSING REMITTING MULTIPLE SCLEROSIS IN CHILE

Authors
Category Systematic review
JournalValue in Health Regional Issues
Year 2019
This article has no abstract
Epistemonikos ID: 07185ceb6fdf72a2e3b66c984c04d4c756011248
First added on: Feb 11, 2025